An ancestral mutation in telomerase causes defects in repeat addition processivity and manifests as familial pulmonary fibrosis.

Jonathan K. Alder, Joy D. Cogan, Andrew F. Brown, Collin J. Anderson, William E. Lawson, Peter M. Lansdorp, John A. Phillips III, James E. Loyd, Julian J.-L. Chen, Mary Armanios

Introduction

Telomerase is a specialized DNA polymerase that synthesizes new telomeres onto chromosome ends by copying from a short template within its integral RNA component. During telomere synthesis, telomerase adds multiple short DNA repeats successively, a property known as repeat addition processivity. However, the consequences of defects in processivity on telomere length maintenance are not fully known. Germine mutations in telomerase cause haploinsufficiency in syndromes of telomere shortening, which most commonly manifest in the age-related disease idiopathic pulmonary fibrosis. We identified two pulmonary fibrosis families that share two non-synonymous substitutions in the catalytic domain of the telomerase reverse transcriptase gene hTERT: V791I and V867M. The two variants fell on the same hTERT allele and were associated with telomere shortening. Genealogy suggested that the pedigrees shared a single ancestor from the nineteenth century, and genetic studies confirmed the two families had a common founder. Functional studies indicated that, although the double mutant did not dramatically affect first repeat addition, hTERT V791I-V867M showed severe defects in telomere repeat addition processivity in vitro. Our data identify an ancestral mutation in telomerase with a novel loss-of-function mechanism. They indicate that telomere repeat addition processivity is a critical determinant of telomere length and telomere-mediated disease.
Author Summary

Mutations in the essential telomerase components cause a spectrum of diseases mediated by short telomeres. Most frequently, these disorders manifest in the lung in an age-related disease: idiopathic pulmonary fibrosis. Telomerase synthesizes telomere repeats using a specialized reverse transcriptase, hTERT, that copies from a short template within its intrinsic RNA. In order to add long telomere tracts, telomerase adds a single repeat followed by additional repeats successively. This property, known as repeat addition processivity, is unique to the telomerase polymerase. We identified two families that shared two unique variants in the catalytic domain of hTERT: V791I and V867M. The variants co-segregated, indicating they are on the same allele, and were associated with short telomeres. Family history suggested the two families may have a single ancestor, and genetic studies confirmed they had a common founder. Telomerase reconstitution indicated that, although the double mutant did not significantly affect telomerase’s ability to add a single telomere repeat, hTERT 791I-867M had severe defects in repeat addition processivity. Our data identify an ancestral mutation in telomerase; this mutation possesses a unique loss-of-function mechanism. Defects in telomere addition processivity are important determinants of telomere length maintenance and of telomere-associated disease.

Telomerase Ancestral Mutation Impairs Processivity

Non-synonymous variants in the reverse-transcriptase domain of hTERT segregate with the pulmonary fibrosis phenotype

In a screen of 75 familial pulmonary fibrosis probands for telomerase mutations, we identified a proband from a family designated number 13 who carried two single nucleotide variants in hTERT. The first was a c.2371G→A transition in exon 7, and the second was c.2599G→A transition in exon 10 (Figure 1A, 1B). These predicted two non-synonymous substitutions in the reverse transcriptase domain: V791I and V867M, respectively (Figure 1C). The single nucleotide variants were absent in 200 ethnically matched controls, as well as in a multi-ethnic control panel examining the hTERT gene sequence [23]. To determine whether these nucleotide substitutions were on the same allele (i.e. in cis) and whether they were associated with the pulmonary fibrosis phenotype, we sequenced genomic DNA from affected family members and examined the segregation: hTERT V791I and V867M were always present together (11 of 11 individuals across 3 generations) suggesting that they were on the same hTERT haplotype (Figure 2). The hTERT variants predicting V791I and V867M segregated with the pulmonary fibrosis diagnosis across four generations in all the individuals we examined (n = 7, 5 directly sequenced, 1 obligate carrier (13.II.5) and 1 probable carrier (13.I.1), Figure 2). The log of the odds ratio (LOD) score of the mutant hTERT allele segregating with the pulmonary fibrosis was significant at 3.3. The segregation of the mutations with the disease phenotype indicated that this double mutant hTERT was likely disease causing.

Two pulmonary fibrosis families share common ancestry

In an independent screen of 24 pulmonary fibrosis families, we identified a second kindred, designated family 143, whose proband carried the identical substitutions in hTERT. In this family, hTERT V791I and hTERT V867M also co-segregated with the pulmonary fibrosis phenotype (Figure 2). Since the two variants were in cis and were rare, we reasoned that Families 13 and 143 may have a single common ancestor. To address this, we carefully queried the genealogy. Independently, members of the two families reported lineage to an individual of the same surname who was born in 1808 in the United States. According to public census records, this ancestor had grandparents who emigrated in the eighteenth century from the British Isles. The genealogy suggested that Families 13 and 143 may be related and that the putative mutation(s) have been present for at least 6 generations, possibly with ancestry as far back as the early nineteenth century. To determine whether Families 13 and 143 shared a common founder, we genotyped polymorphic microsatellite and minisatellite sequences that flank as well as fall within the hTERT gene (Figure S1A, S1B). In all the individuals who carried the hTERT substitutions at 791 and 867 positions, we identified a shared haplotype block which was both within and flanked hTERT (Figure S1A, S1B). These data, together with the family histories, indicated that Families 13 and 143 shared a common ancestor who carried the double mutant hTERT allele.

hTERT 791I-867M causes defects in repeat addition processivity in vitro

To determine the functional significance of the hTERT 791I and 867 variants, we first examined the evolutionary conservation of the hTERT V791I and V867 residues. hTERT V791I fell within the insertion in finger domain (IFD) between the A and B motifs of the reverse transcriptase domain [10,26], a telomerase specific motif (Figure 1B, 1C). hTERT V867 fell within the universal reverse transcriptase motif C, and was adjacent to the invariant aspartic acid residues which are essential for the catalytic function of telomerase and other reverse transcriptases [4] (Figure 1B, 1C). The sequence alignment from representative species showed that these two residues are generally conserved as hydrophobic amino acids in most organisms, and are therefore potentially important for telomerase function.

To directly examine whether the variant hTERT affects telomerase activity, we reconstituted the mutant telomerase and measured enzyme activity in vitro. At standard assay conditions of 1 mM nucleotide concentrations [8,12,13,20,27], the 791I alone did not have obvious defects in activity or processivity (Figure 3A, lane 3). A minor inter-repeat pause was present for 867M; this has been previously suggested to be due to nucleotide affinity defects...
This pause was also present in the 791I-867M double mutant (Figure 3A, lane 5). However, the overall activity and processivity of 867M and 791I-867M were not affected (Figure 3A, lanes 4 and 5). For comparison, we measured the activity of a known hTERT mutation L55Q previously identified in a family with pulmonary fibrosis [13]. This mutant showed a significant decrease in overall activity (Figure 3A, lane 2).

Since the segregation and the genetic evidence supported the 791I-867M being a pathogenic allele, we assayed its function at nucleotide concentrations that are closer to the estimated Km for telomerase [29,30]. The lower concentrations also more closely mimic estimates of intra-nuclear nucleotide concentrations (10 μM) [31–33]. Under these conditions, there was little effect on the synthesis of the first repeat compared with wildtype telomerase (Figure 3A–3D).

We next measured repeat addition processivity. Notably, hTERT 867M and the double mutant hTERT had significant decreases in repeat addition processivity (Figure 3A and 3E). The decreased repeat addition processivity was not seen for the 55Q and 791I alleles (Figure 3A and 3E). This decrease was evident by the lower intensity of high molecular weight repeat products relative to the first product (Figure 3A, lane 6 compared with lanes 9 and 10). For example, by the fourth

---

**Figure 1.** Position and conservation of non-synonymous variants in hTERT shared by pulmonary fibrosis families 13 and 143 probands. A,B. Chromatograms of single nucleotide variants predict non-synonymous amino acid substitutions. The first was a c.2371G→A transition in exon 7 (A), and the second was c.2599G→A transition in exon 10 (B). C. Panel shows conserved hTERT motifs shared with other TERTs. The non-synonymous amino acid variant residues are indicated within the reverse transcriptase domain. hTERT V791 falls in the ID domain between the A and B motifs, and hTERT V867 is adjacent to the invariant motif C aspartic acid residues which are essential for reverse transcriptase function and are indicated by *.

Alignment of TERT sequence across 14 species indicates that both V791 and V867 fall within conserved motifs.

doi:10.1371/journal.pgen.1001352.g001
repeat, both hTERT 867M and 791I-867M had approximately a 10-fold reduction in telomere product compared with wildtype telomerase (Figure 3E). The decrease in processivity was independent of the hTERT epitope tag used in affinity purification, as we saw the same degree of impairment for 867M and 791I-867M whether a C-terminal HA or N-terminal FLAG epitope was used (not shown). To exclude the possibility that the double mutant hTERT may have dominant negative effects, we performed mixing studies of wildtype and 791I-867M and found no additional decreases in activity or processivity (not shown). These data indicated that although hTERT 791I and 867M co-segregate with the disease phenotype, the 867M mutation appears to be the pathogenic variant and predominantly affects telomere repeat addition processivity in vitro.

**Mutant TERT is associated with short telomere length**

Telomerase haploinsufficiency causes telomere shortening and the severity of the consequent phenotypes correlates with the telomere length [20,34]. To examine if the mutant telomerase is associated with telomere shortening, we measured telomere length in family members using combined flow cytometry and fluorescence in situ hybridization (flow-FISH) [12,13]. In all cases, mutation carriers had lymphocyte telomere lengths below the 10th percentile of a normal distribution compared with age-matched controls, and in two individuals, the telomere length fell at or below the 1st percentile (Figure 4, P = 0.039, paired t-test). Therefore the mutant hTERT is associated with telomere shortening in mutation carriers.

**A spectrum of telomere-mediated disease is associated with ancestral TERT mutation**

Syndromes of telomere shortening manifest as degenerative disease in the lung, liver and bone marrow, and a subset of pulmonary fibrosis families falls on this spectrum [11,13]. To examine whether the mutant TERT leads to the full spectrum of telomere-mediated disease, we characterized the clinical phenotypes in families 13 and 143. Of the 18 genetically affected individuals in the two pedigrees, 11 had pulmonary disease. In the majority of cases (7 of 11, 64%), the interstitial lung disease met the criteria for usual interstitial pneumonia/IPF (Figure 5A, 5B and Table S1). In affected individuals, the onset of disease was in adulthood with a mean age of 56 (range 32–67). There was very subtle genetic anticipation for the age at death across the generations we could examine (e.g. age 61 and mean age 56 for generations I and II respectively in family 13, Table S1). Two individuals at the age of 50 and 51 reported chronic liver function abnormalities that were unexplained after a thorough work-up. We identified subclinical cytopenias in one individual (age 50), and one individual was diagnosed with AML at age 67 and subsequently died from complications of interstitial lung disease (Table S1). We clinically examined the probands and their relatives for the typical mucocutaneous features of dyskeratosis congenita but did not identify any signs of skin hyperpigmentation, nail dystrophy or oral leukoplakia. Therefore the telomerase defect we identified in families 13 and 143 appears to primarily cause adult-onset phenotypes. These phenotypes are clinically most prominent in the lung, but features of the full spectrum of a telomere syndrome manifest at lower frequency including subclinical cytopenias, liver function abnormalities and AML.

**Unaffected siblings of mutation carriers have short telomeres**

Telomere length is a heritable trait and parental telomere length determines offspring telomere length even when telomerase is wildtype [34,36,37]. In a large dyskeratosis congenita family, siblings of mutation carriers were shown to have short telomeres; however telomere-related phenotypes in these individuals have not been previously reported [38]. Since the hTERT 791I-867M mutation was associated with short telomeres, we examined whether their non-mutation carrier relatives may also have short telomeres. In 4 individuals we examined, the lymphocyte telomere length was below the 10th percentile compared with age-matched controls, and in two individuals, the telomere length fell at or below the 1st percentile (Figure 4, P = 0.039, paired t-test). To determine whether short telomeres may be a risk factor for developing telomere-mediated disease, we examined the clinical phenotypes of the individuals who did not carry the hTERT 791I-867M allele but who had short telomeres. We identified one patient who presented to our clinic with shortness of breath at the
Figure 3. The ancestral mutant telomerase affects repeat addition processivity in vitro. A. Telomerase activity assay of non-synonymous hTERT variants identified in family 13 and 143 probands. L55Q was previously identified in a pulmonary fibrosis family and known to compromise catalysis. Telomerase activity assay at high nucleotide (1 mM) concentrations on the left shows no defects in catalytic activity or processivity for hTERT V791I and V867M or the double mutant. At lower nucleotide concentration (10 μM), hTERT 867M and hTERT V791I-V867M both show defects in repeat addition processivity as evidenced by the decreased intensity of the high molecular weight products relative to the first repeat. Low exposure image of the internal loading control is shown below. B. Low exposure image of the gel shown in (A) is shown to visualize the +1, +2, and +3 nucleotide bands clearly. C. SDS-PAGE of 35S labeled hTERT used in (A) to monitor the expression of in vitro synthesized hTERTs. D. Quantitation of
age of 53. His history was significant for a lifelong history of cigarette use (greater than 50 pack-years). The patient’s CAT scan showed a mixed picture of interstitial lung disease with ground glass infiltrates and emphysema (Figure 5C, 5D), and lung biopsy confirmed the presence of interstitial fibrosis on the background of bronchiolitis. Although cigarette smoke has been shown to be associated with short telomeres and is known to contribute to the risk of both emphysema and pulmonary fibrosis [39], it is intriguing to consider the possibility that parental telomere length may have contributed to the telomere shortening in this individual and to his risk of lung disease.

Discussion

Repeat addition processivity is a unique biochemical attribute of the telomerase reverse transcriptase, and here we show it may be critical for telomere maintenance in vivo. Telomerase-intrinsic and extrinsic factors have been implicated in repeat addition processivity [8–10], and our study suggests that inherited defects that affect this unique property of the telomerase enzyme may contribute to telomere length heterogeneity and to telomere-mediated disease. Although individuals in the two kindreds we describe carried two in cis variants in hTERT, our biochemical studies suggest that hTERT 867M is likely the functionally important mutation. As such, the hTERT 791I rare variant may serve as a useful genetic marker and, along with the 867M, can identify other families with shared ancestry to the families we report herein. Single nucleotide titration studies have implicated hTERT V867 to be important in telomerase function [28]. Studies of the Tetrahymena thermophila TERT have also implicated the orthologous residue adjacent to V867 in repeat addition processivity [40]. These observations, along with our findings, indicate that residues within motif C of the telomerase reverse transcriptase domain are important determinants of telomere repeat addition processivity. Several mechanisms of telomerase haploinsufficiency have been previously reported for disease causing mutations including loss of hTR stability, impaired association of hTR with hTERT, and loss of catalytic function [13,20,22,24,25]. In this study, the strong genetic evidence linking the mutant TERT to a known telomere-mediated disease, and the evidence of telomere shortening in vivo, indicate that the mutant TERT affects telomere maintenance. Our in vitro biochemical studies show that the mutant TERT is defective in repeat addition processivity, pointing to this as the likely mechanism for the loss of telomerase function and the consequent organ failure.

We report on an ancestral mutation in hTERT which manifested independently in two pulmonary fibrosis families. To our knowledge, hTERT 791I-867M is the most ancient telomerase mutation, and it is likely that other kindreds with familial pulmonary fibrosis and other features of telomere syndromes will be subsequently found to share ancestry with these pedigrees. In contrast to a family with a functionally null hTERT mutation where genetic anticipation was striking and caused a two decade earlier onset of disease across each generation [20], hTERT 791I-
867M causes only subtle anticipation across the generation spans we studied. This observation suggests that the extent of genetic anticipation may correlate with the degree of telomerase loss-of-function thus making genetic anticipation more difficult to detect across consecutive generations in families that carry hypomorphic mutations. Telomerase preferentially elongates the shortest telomeres [41,42], and our functional studies which show intact single repeat synthesis, point to the fact that the ancestral hTERT 791I-867M may have the capacity to add initial telomere tracts, thus healing the shortest telomeres. However, with successive telomere repeats, telomere addition is less efficient. Loss of telomere repeat addition processivity may therefore be a manifestation of more hypomorphic mutations, and therefore adult-onset phenotypes, as the shortest telomeres may still be elongated, albeit with shorter telomere tracts.

In this multi-generation study, although pulmonary fibrosis was the most common manifestation in mutation carriers, several individuals had extra-pulmonary manifestations of telomere-mediated disease. One individual had avascular necrosis and macrocytosis, two individuals reported history of cryptogenic liver function abnormalities, and one patient had a history of AML prior to the diagnosis of interstitial lung disease. Bone marrow failure, avascular necrosis and cryptogenic liver cirrhosis are all known complications of dyskeratosis congenita [17], and pulmonary fibrosis families with mutant telomerase genes have been known to have an increased incidence of aplastic anemia, a common complication of dyskeratosis congenita [13]. AML, often arising in the setting of myelodysplasia, has been recently reported as a first manifestation of mutant telomerase genes [18,19], and it is possible that families with pulmonary fibrosis due to telomerase deficiency also have an increased incidence of AML. In 8 consecutive pulmonary fibrosis families with known hTR or hTERT mutations, including the 2 we report herein, there was a total of 3 first degree relatives of IPF probands who died with AML at ages 25, 59, 68. Dyskeratosis congenita patients are known to have an increased incidence of AML [16]. These observations highlight the fact that a subset of families with pulmonary fibrosis falls on the same spectrum as dyskeratosis congenita and that the diagnosis of telomere syndrome in these patients is relevant to their clinical work-up and surveillance. Pulmonary fibrosis patients should be queried about a personal or family history of AML, along with aplastic anemia, as part of the screening history for a telomere syndrome.

In summary, an ancestral mutation within the reverse transcriptase domain of telomerase manifests as familial pulmonary fibrosis and causes defects in telomere repeat addition processivity. Genetic factors that affect repeat addition processivity may be important determinants of telomere length heterogeneity across populations, and can contribute to understanding the inherited basis of telomere-mediated disease.

**Methods**

**Subjects and ethics statement**

Subjects were recruited through the Vanderbilt Familial Pulmonary Fibrosis Registry and gave written informed consent [13]. The study was approved by the institutional review boards of both Vanderbilt and Johns Hopkins Universities. The probands from Families 13 and 143, and the majority of mutation carrier and non-carrier relatives were clinically evaluated. Primary medical records were used to document the diagnoses listed in Table S1. We used the consensus classification to phenotype the idiopathic interstitial lung disease [43].

**Genotyping and telomere length measurement**

Genomic DNA was extracted from peripheral blood using standard methods. We sequenced hTERT [13] and confirmed variants bidirectionally. Control DNA was obtained from Corriel...
repository with self-reported Northern European ethnicity, similar to the families we studied. We used Merlin to calculate a single point LOD score [44], under the assumption of autosomal dominant inheritance and a 1/10,000 population frequency of idiopathic interstitial lung disease. We determined allele size of microsatellites DSS1981 (Forward-ctctgacaatcatga, Reverse-gacatctggaagtc) and DSS2005 (Forward-ctctgagggttttagtc, Reverse-ccccaggtttcagt) using fluorescent labeled forward primers obtained from Qiagen (Valencia, CA). PCR products were analyzed on the ABI Genome Analyzer instrument (Applied Biosystems). Pheroxgrams were interpreted manually to determine allele size. We amplified and genotyped mini-satellites/variable number of tandem repeats within hTERT: 2–2 (intron 2) and 6–1 (intron 6) as published [45]. We determined the number of tandem repeats using gel electrophoresis. Telomere length was measured by flow-FISH on peripheral blood mononuclear cells [13].

Telomerase activity assay
TERT protein alignment was generated using CLUSTALW followed by BoxShade analysis (v.3.21), and we used NP_937983 for the hTERT protein sequence. TERT sequences were obtained from http://telomerase.asu.edu [46]. To test the activity and processivity of the telomerase mutants, we expressed each of them in vitro and quantified function using a direct telomerase activity assay as previously described [10]. All telomerase variants were reconstituted using the TNT (transcription and translation) Quick Coupled rabbit reticulocyte lysate system (Promega) following manufacturer’s instructions. Briefly, recombinant N-FLAG tagged hTERT was expressed in 10 μL of TNT lysate with [35S] labeled methionine at 30°C for 60 minutes. To obtain active telomerase, in vitro transcribed hTR pseudoknot (nt 32–195) and CR4-CR5 (nt 239–328) fragments were each added to a concentration of 8 μM and incubated at 30°C for 30 minutes. To avoid variations in the quality of telomerase reconstituted, the wildtype and variant hTERT proteins were all expressed from the same batch of TNT lysate and the reconstituted enzymes were assayed immediately without freezing. To assay the activity and processivity of each telomerase variant, a 10 μl reaction was carried out using 3 μl of in vitro reconstituted telomerase in the presence of 1X PE buffer (50 mM Tris-HCl, pH 8.3, 50 mM KCl, 2 mM DTT, 3 mM MgCl2, and 1 mM spermidine) and 2 pmol of 5′-32P end-labeled (TTAGGG)n telomere primer at 30°C for 1 h. Deoxynucleotides (dATP, dTTP, and dGTP) were also included at concentrations of either 1 mM or 10 μM, as indicated. Reactions were terminated by phenol-chloroform extraction followed by ethanol precipitation and incubation at 37°C for 1 h. Deoxynucleotides were analyzed on the ABI Genome Analyzer instrument (Applied Biosystems). Pheroxgrams were interpreted manually to determine the intensity of each repeat band, normalized to the intensity of the first repeat, and plotted against the repeat number [9].

Supporting Information

Figure S1 Pulmonary fibrosis families 13 and 143 share a common haplotype block flanking and within the hTERT locus. A. Pedigrees of Families 13 and 143 with numbers below indicate genotype at microsatellite DSS1981, variable number of tandem repeats (VNTR) 6–1 in intron 6, and 2–2 in intron 2, as well as microsatellite DSS2005, respectively from top to bottom. The shared haplotype block is shown in bold and is shared by all mutation carriers in families 13 and 143. * Refers to a mutation carrier who shares the common haplotype block except at DSS1981 where the allele is shorter by a single dinucleotide repeat; this may be related to polymerase slippage or a recombination event. The symbols are identified in the key, and completely filled symbols indicate clinically affected individuals who carry the double mutant TERT. B. Schema of hTERT locus indicating the location of the genotyped micro- and mini-satellites genotyped in this study. The vertical blocks within the hTERT locus represent the 16 exons within the hTERT gene. Found at: doi:10.1371/journal.pgen.1001352.s001 (1.51 MB EPS)

Table S1 Clinical Features of Probands and Mutation Carriers

| n=10 |
|---|
| Found at: doi:10.1371/journal.pgen.1001352.s002 (0.04 MB DOC) |

Acknowledgments
We are grateful to the family members who participated in this study. We are thankful to Dr. Carol Greider for critical reading of the manuscript. We are grateful to Erin Parry for helpful discussions, Mingyi Xie for the telomerase constructs, Cheryl Markin for assistance with coordinating the study, and Cate Kiefe for help with the pedigree drawings.

Author Contributions
Conceived and designed the experiments: JKA JEL JJLC MA. Performed the experiments: JKA JDC AFB CJA. Analyzed the data: JKA JDC AFB CJA WEL JEL JJLC MA. Contributed reagents/materials/analysis tools: JDC PML JAP JEL JJLC MA. Wrote the paper: MA.

References
1. Greider CW, Blackburn EH (1985) Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43: 405–413.
2. Greider CW, Blackburn EH (1987) The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 51: 887–898.
3. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, et al. (1995) The RNA component of human telomerase. Science 269: 1236–1241.
4. Lingner J, Hughes TR, Shrevechenko A, Mann M, Lundblad V, et al. (1997) Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 276: 561–567.
5. Greider CW, Blackburn EH (1989) A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 337: 341–357.
6. Autesserre C, Lue NF (2006) The structure and function of telomerase reverse transcriptase. Annu Rev Biochem 75: 493–517.
7. Greider CW (1991) Telomerase is processive. Mol Cell Biol 11: 4572–4580.
8. Chen JL, Greider CW (2003) Determinants in mammalian telomerase RNA that mediate enzyme processivity and cross-species incompatibility. Embo J 22: 304–314.
9. Wang F, Podell ER, Zaug AJ, Yang Y, Baciu P, et al. (2007) The POT1-TPP1 telomere complex is a telomerase processivity factor. Nature 445: 506–510.
10. Xie M, Podlevsky JD, QZ X, Bley CJ, Chen JJ (2008) A novel motif in telomerase reverse transcriptase regulates telomere repeat addition rate and processivity. Nucleic Acids Res 38: 1912–1926.
11. Armanios M (2009) Syndromes of telomere shortening. Annu Rev Genomics Hum Genet 10: 43–61.
12. Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, et al. (2008) Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 105: 13051–13056.
13. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, et al. (2007) Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 356: 1317–1326.
14. Cronkhite JT, Xing C, Raghu G, Chinn KM, Torres F, et al. (2008) Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 178: 729–737.
15. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, et al. (2007) Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A 104: 7592–7597.
16. Alter BP, Giri N, Savage SA, Rosenberg PS (2009) Cancer in dyskeratosis congenita. Blood 113: 6534–6537.

17. Kirwan M, Dolk I (2008) Dyskeratosis congenita: a genetic disorder of many faces. Clin Genet 73: 103–112.

18. Calado RT, Regal JA, Hills M, Yewdell WT, Dahmann DF, et al. (2009) Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci U S A 106: 1187–1192.

19. Kirwan M, Vallianny T, Marrone A, Walsh AJ, Beswick R, et al. (2009) Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum Mutat 30: 1567–1573.

20. Armanios M, Chen JI, Chang YP, Brodsky RA, Hawkins A, et al. (2005) Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A 102: 15960–15964.

21. Diaz de Leon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raugh G, et al. (2010) Telomere lengths, pulmonary fibrosis and telomerase (TEKT) mutations. PLoS ONE 5: e10930. doi:10.1371/journal.pone.0010930.

22. Vallianny T, Marrone A, Goldman F, Dearlove A, Besder M, et al. (2001) The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 413: 432–435.

23. Yamaguchi H, Calado RT, Ly H, Kajigaya S, Baerlocher GM, et al. (2005) Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 352: 1413–1424.

24. Ly H, Calado RT, Allard P, Baerlocher GM, Lanshep PM, et al. (2005) Functional characterization of telomerase RNA variants found in patients with hematologic disorders. Blood 105: 2332–2339.

25. Robart AR, Collins K (2007) Investigation of human telomerase holoenzyme assembly, activity, and processivity using disease-linked subunit variants. J Biol Chem 282: 4375–4386.

26. Lue NF, Lin YC, Mian IS (2003) A conserved telomerase motif within the catalytic domain of telomerase reverse transcriptase is specifically required for repeat addition processivity. Mol Cell Biol 23: 8440–8449.

27. Chen J, Aiste CM, Harrison DE (1999) Development and aging of primitive hematopoietic stem cells in BALB/cBy mice. Exp Hematol 27: 928–935.

28. Drosopoulos WC, Prasad VR (2007) The active site residue Valine 867 in human telomerase reverse transcriptase influences nucleotide incorporation and fidelity. Nucleic Acids Res 35: 1155–1168.

29. Jarstfer MB, Cech TR (2000) A mutant of Tetrahymena aediculatus telomerase processivity: evidence for product-assisted translocation. Biochemistry 39: 15325–15332.

30. Arion D, Berkow G, Gu Z, Wainberg MA, Parniak MA (1996) The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase. J Biol Chem 271: 19860–19864.

31. Golinski MP, Hughes SH (2002) Nontemplated nucleotide addition by HIV-1 reverse transcriptase. Biochemistry 41: 5894–5906.

32. Skoog L, Bjursell G (1974) Nuclear and cytoplasmic pools of deoxynucleobase-triphosphates in Chinese hamster ovary cells. J Biol Chem 249: 6434–6438.

33. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, et al. (2005) Obesity, cigarette smoking, and telomere length in women. Lancet 366: 662–664.

34. Hao LY, Armanios M, Strong MA, Karim B, Feldser DM, et al. (2005) Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell 123: 1121–1131.

35. Alter BP, Baerlocher GM, Savage SA, Chanock SJ, Weikler BB, et al. (2007) Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 110: 1439–1447.

36. Armanios M, Alder JK, Parry EM, Karin B, Strong MA, et al. (2009) Short telomeres are sufficient to cause the degenerative defects associated with aging. Am J Hum Genet 85: 823–832.

37. Goldman F, Bosarich R, Kulikarni S, Freeman S, Du HY, et al. (2005) The effect of TERC haploinsufficiency on the inheritance of telomere length. Proc Natl Acad Sci U S A 102: 17119–17124.

38. Valdes AM, Andrew T, Gardiner JP, Kimura M, Olsner E, et al. (2005) Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 110: 1439–1447.

39. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias (2002) This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165: 277–304.

40. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 110: 1439–1447.